On November 20, 2023 CBMG Holdings (the "Company") reported that following the spin-off of the Company’s stem cell business division, it has changed its name to AbelZeta Pharma, Inc. ("AbelZeta"), which will focus on immune cell business (Press release, AbelZeta, NOV 20, 2023, View Source [SID1234637956]). The spin-off, approved by the Company’s board of directors and shareholders, allows AbelZeta to focus greater resources on the development of immune cell therapy for cancer and Inflammation & Immunology (I&I) diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe the name AbelZeta best reflects our Company’s culture and values and is the next step in our growth as a commercially focused immune cell therapeutics company," said Tony (Bizuo) Liu, Chairman and CEO of the Company. "Abel is an ancient name long associated with humility, integrity, and conviction, and the Greek letter ζ, or zeta, is a widely recognized component of the T-cell receptor in the immune cell research community. The name AbelZeta articulates our confidence in the T-cell based therapies to deliver transformative treatments to address aggressive cancers and serious immune disorders.

"The Company currently has 13 ongoing clinical studies in its immune cell pipeline in the United States and in China.